Cancer and Leukemia Group B

描述（由申请人提供）：参与CALGB仍然是芝加哥大学癌症研究事业的主要焦点。这一竞争性更新提议继续和扩大我们在CALGB临床、治疗和相关科学方面的广泛参与。我们的承诺是将创新治疗方法的早期测试结果和有关临床试验方法的问题带到合作小组环境中，在那里我们的病人的护理标准是确定的。我们将继续在科学委员会领导、行政领导和研究主席方面为CALGB提供领导。我们将把在芝加哥大学进行的转化研究成果提供给CALGB，并提供核心实验室协助CALGB进行转化研究。年轻的教师和研究员将接受临床研究方面的培训，并鼓励他们通过参加CALGB来发展自己的职业生涯。此外，我们将继续并改善我们在CALGB试验中积累的良好记录，无论是在芝加哥大学本身，还是通过继续招募、教育和支持社区附属机构。我们将继续并扩大项目，以接触到我们周围的少数民族患者，为他们提供参与临床试验的机会。CALGB作为一种改善当前和未来癌症患者护理的工具，贯穿于该机构的临床癌症研究，我们期待着在即将到来的拨款期内为我们的癌症患者带来基础科学界令人兴奋的发展。

DESCRIPTION (provided by applicant): Participation in CALGB continues to be a major focus of the cancer research enterprise at the University of Chicago. This competing renewal proposes to continue and expand our extensive and broad involvement in the clinical, therapeutic and correlative science aspects of CALGB. Our commitment is to bring results of early testing of innovative therapeutic approaches and questions about clinical trials methodology to the cooperative group setting, where the standard of care for our patients is defined. We will continue to supply leadership for CALGB in terms of scientific committee leadership, administrative leadership, and study chairs. We will bring the results of translational research performed at the University of Chicago to the CALGB, and will supply core laboratories to assist CALGB in performing translational research. Young faculty and fellows will be trained in clinical research and encouraged to develop their careers through participation in CALGB. In addition, we will continue and improve our strong record of accrual to CALGB trials, both at the University of Chicago itself and through continued recruitment, education and support of community affiliates. We will continue and expand programs to reach out to minority patients in our immediate surroundings to offer them the opportunity for clinical trial participation. An overwhelming commitment to CALGB as a vehicle to improve the care of current and future cancer patients runs throughout clinical cancer research at the institution, and we look forward to helping bring the exciting developments of the basic science community to our cancer patients in the coming grant period.